Kennis & ervaring
Specialisme / subspecialisme: alle richtingen, met speciale onderzoeksaandacht voor sarcomen, neuroblastoom2006-2010 promotie-onderzoek Sanquin, Amsterdam
2012-2017: opleiding kinderarts WKZ/UMCU
2018-heden: fellow kinderoncologie Prinses Maxima Centrum
Wetenschappelijk
2006 - 2010: Minimal residual disease bepaling in neuroblastomen (promotie), Sanquin Amsterdam
2017- heden: Minimal residual disease bepaling in rhabdomyosarcomen (Post doc), Prinses Maxima centrum
Mijn publicaties op pubmed.
- Van Wezel EM, Stutterheim J, Vree F et al. Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma. Pediatr Blood Cancer. 2015 Aug;62(8):1368-73.
- Stutterheim J, Ait Ichou F, den Ouden E, et al. Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma. Clin Cancer Res. 2012 Feb 1;18(3):808-14.
- Stutterheim J, Zappeij-Kannegieter L, Versteeg R, et al. The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma. Eur J Cancer. 2011 May;47(8):1193-202.
- Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, et al. Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers. Clin Chem. 2009 Jul;55(7):1316-26.
- Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, et al. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma. J Clin Oncol. 2008 Nov 20;26(33):5443-9.
BIG-registratie
49066587501
Contactgegevens
Telefoon 088-9729559
Aanwezig op: dinsdag t/m vrijdag